Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma
Open accessThe DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Abstract
Importance: Coronavirus disease 2019 (COVID-19) is a pandemic with no specific therapeutic agents and substantial mortality. It is critical to find new treatments. Objective: To determine whether convalescent plasma transfusion may be beneficial in the treatment of critically ill patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Design, Setting, and Participants: Case series of 5 critically ill patients with laboratory-confirmed COVID-19 and acute respiratory distress syndrome (ARDS) who met the following criteria: severe pneumonia with rapid progression and continuously high viral load despite antiviral treatment; Pao2/Fio2 <300; and mechanical ventilation. All 5 were treated with convalescent plasma transfusion. The study was conducted at the infectious disease department, Shenzhen Third People's Hospital in Shenzhen, China, from January 20, 2020, to March 25, 2020; final date of follow-up was March 25, 2020. Clinical outcomes were compared before and after convalescent plasma transfusion. Exposures: Patients received transfusion with convalescent plasma with a SARS-CoV-2-specific antibody (IgG) binding titer greater than 1:1000 (end point dilution titer, by enzyme-linked immunosorbent assay [ELISA]) and a neutralization titer greater than 40 (end point dilution titer) that had been obtained from 5 patients who recovered from COVID-19. Convalescent plasma was administered between 10 and 22 days after admission. Main Outcomes and Measures: Changes of body temperature, Sequential Organ Failure Assessment (SOFA) score (range 0-24, with higher scores indicating more severe illness), Pao2/Fio2, viral load, serum antibody titer, routine blood biochemical index, ARDS, and ventilatory and extracorporeal membrane oxygenation (ECMO) supports before and after convalescent plasma transfusion. Results: All 5 patients (age range, 36-65 years; 2 women) were receiving mechanical ventilation at the time of treatment and all had received antiviral agents and methylprednisolone. Following plasma transfusion, body temperature normalized within 3 days in 4 of 5 patients, the SOFA score decreased, and Pao2/Fio2 increased within 12 days (range, 172-276 before and 284-366 after). Viral loads also decreased and became negative within 12 days after the transfusion, and SARS-CoV-2-specific ELISA and neutralizing antibody titers increased following the transfusion (range, 40-60 before and 80-320 on day 7). ARDS resolved in 4 patients at 12 days after transfusion, and 3 patients were weaned from mechanical ventilation within 2 weeks of treatment. Of the 5 patients, 3 have been discharged from the hospital (length of stay: 53, 51, and 55 days), and 2 are in stable condition at 37 days after transfusion. Conclusions and Relevance: In this preliminary uncontrolled case series of 5 critically ill patients with COVID-19 and ARDS, administration of convalescent plasma containing neutralizing antibody was followed by improvement in their clinical status. The limited sample size and study design preclude a definitive statement about the potential effectiveness of this treatment, and these observations require evaluation in clinical trials.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China
Huang, C., Wang, Y., Li, X., Ren, L., Zhao, J., Hu, Y., Zhang, L., Fan, G., Xu, J., Gu, X., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30183-5 · Cited by 48,884
Wu, Z., & McGoogan, J. M. (2020) · JAMA · doi:10.1001/jama.2020.2648 · Cited by 17,016 · cited 2×
“Patients Patients with laboratory confirmed COVID-19, diagnosed using quantitative reverse transcriptase–polymerase chain reaction (qRT-PCR) (GeneoDX Co, Ltd)13 were eligible to receive convalescent plasma treatment if they fulfilled the following criteria: (1) had severe pneumonia with rapid progression and continuou…”
MethodFatal outcome of human influenza A (H5N1) is associated with high viral load and hypercytokinemia.
de Jong, M. D., Simmons, C. P., Thanh, T. T., Hien, V. M., Smith, G. J. D., Chau, T. N. B., Hoang, D. M., Van Vinh Chau, N., Khanh, T. H., Dong, V. C., et al. (2006) · Nature Medicine · doi:10.1038/nm1477 · Cited by 1,858
Drug treatment options for the 2019-new coronavirus (2019-nCoV)
Lu, H. (2020) · BioScience Trends · doi:10.5582/bst.2020.01020 · Cited by 1,133
Convalescent plasma as a potential therapy for COVID-19
Chen, L., Xiong, J., Bao, L., & Shi, Y. (2020) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(20)30141-9 · Cited by 1,038
Self-citationMair-Jenkins, J., Saavedra-Campos, M., Baillie, J. K., Cleary, P., Khaw, F.-M., Lim, W. S., Makki, S., Rooney, K. D., Convalescent Plasma Study Group, Nguyen-Van-Tam, J. S., et al. (2015) · Journal of Infectious Diseases · doi:10.1093/infdis/jiu396 · Cited by 983
Use of convalescent plasma therapy in SARS patients in Hong Kong
Cheng, Y., Wong, R., Soo, Y. O. Y., Wong, W. S., Lee, C. K., Ng, M. H. L., Chan, P., Wong, K. C., Leung, C. B., & Cheng, G. (2005) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-004-1271-9 · Cited by 958
Hung, I. F., To, K. K., Lee, C.-K., Lee, K.-L., Chan, K., Yan, W.-W., Liu, R., Watt, C.-L., Chan, W.-M., Lai, K.-Y., et al. (2011) · Clinical Infectious Diseases · doi:10.1093/cid/ciq106 · Cited by 678
Evaluation of Convalescent Plasma for Ebola Virus Disease in Guinea
van Griensven, J., Edwards, T., de Lamballerie, X., Semple, M. G., Gallian, P., Baize, S., Horby, P. W., Raoul, H., Magassouba, N., Antierens, A., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1511812 · Cited by 536
The unique characteristics of COVID-19 coagulopathy
Iba, T., Levy, J. H., Connors, J. M., Warkentin, T. E., Thachil, J., & Levi, M. (2020) · Critical Care · doi:10.1186/s13054-020-03077-0 · Cited by 533
Cited by
Items 101–133 of 133
Pharmaco-Immunomodulatory Therapy in COVID-19
Rizk, J. G., Kalantar-Zadeh, K., Mehra, M. R., Lavie, C. J., Rizk, Y., & Forthal, D. N. (2020) · Drugs · doi:10.1007/s40265-020-01367-z · Cited by 288
COVID-19 and Cancer: a Comprehensive Review
Gosain, R., Abdou, Y., Singh, A., Rana, N., Puzanov, I., & Ernstoff, M. S. (2020) · Current Oncology Reports · doi:10.1007/s11912-020-00934-7 · Cited by 285
Convalescent plasma therapy for B-cell–depleted patients with protracted COVID-19
Hueso, T., Pouderoux, C., Péré, H., Beaumont, A.-L., Raillon, L.-A., Ader, F., Chatenoud, L., Eshagh, D., Szwebel, T.-A., Martinot, M., et al. (2020) · Blood · doi:10.1182/blood.2020008423 · Cited by 281
A therapeutic neutralizing antibody targeting receptor binding domain of SARS-CoV-2 spike protein
Kim, C., Ryu, D.-K., Lee, J., Kim, Y.-I., Seo, J.-M., Kim, Y.-G., Jeong, J.-H., Kim, M., Kim, J.-I., Kim, P., et al. (2021) · Nature Communications · doi:10.1038/s41467-020-20602-5 · Cited by 281
Structural basis for the neutralization of SARS-CoV-2 by an antibody from a convalescent patient
Zhou, D., Duyvesteyn, H. M. E., Chen, C.-P., Huang, C.-G., Chen, T.-H., Shih, S.-R., Lin, Y.-C., Cheng, C.-Y., Cheng, S.-H., Huang, Y.-C., et al. (2020) · Nature Structural & Molecular Biology · doi:10.1038/s41594-020-0480-y · Cited by 274
Self-citationCOVID-19: Emergence, Spread, Possible Treatments, and Global Burden
Keni, R., Alexander, A., Nayak, P. G., Mudgal, J., & Nandakumar, K. (2020) · Frontiers in Public Health · doi:10.3389/fpubh.2020.00216 · Cited by 272
Hospital Preparedness for COVID-19: A Practical Guide from a Critical Care Perspective
Griffin, K. M., Karas, M. G., Ivascu, N. S., & Lief, L. (2020) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.202004-1037cp · Cited by 267
The role of IL-6 and other mediators in the cytokine storm associated with SARS-CoV-2 infection
Copaescu, A., Smibert, O., Gibson, A., Phillips, E. J., & Trubiano, J. A. (2020) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2020.07.001 · Cited by 262
Dynamic changes in anti-SARS-CoV-2 antibodies during SARS-CoV-2 infection and recovery from COVID-19
Li, K., Huang, B., Wu, M., Zhong, A., Li, L., Cai, Y., Wang, Z., Wu, L., Zhu, M., Li, J., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-19943-y · Cited by 260
Self-citationDatta, P. K., Liu, F., Fischer, T., Rappaport, J., & Qin, X. (2020) · Theranostics · doi:10.7150/thno.48076 · Cited by 257
Alijotas-Reig, J., Esteve-Valverde, E., Belizna, C., Selva-O'Callaghan, A., Pardos-Gea, J., Quintana, A., Mekinian, A., Anunciacion-Llunell, A., & Miró-Mur, F. (2020) · Autoimmunity Reviews · doi:10.1016/j.autrev.2020.102569 · Cited by 235
Wang, K., Long, Q.-X., Deng, H.-J., Hu, J., Gao, Q.-Z., Zhang, G.-J., He, C.-L., Huang, L.-Y., Hu, J.-L., Chen, J., et al. (2021) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa1143 · Cited by 218
Chloroquine or hydroxychloroquine for prevention and treatment of COVID-19
Singh, B., Ryan, H., Kredo, T., Chaplin, M., & Fletcher, T. (2021) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd013587.pub2 · Cited by 214
Methodological quality of COVID-19 clinical research
Jung, R. G., Di Santo, P., Clifford, C., Prosperi-Porta, G., Skanes, S., Hung, A., Parlow, S., Visintini, S., Ramirez, F. D., Simard, T., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-21220-5 · Cited by 189
Bohn, M. K., Lippi, G., Horvath, A., Sethi, S., Koch, D., Ferrari, M., Wang, C.-B., Mancini, N., Steele, S., & Adeli, K. (2020) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2020-0722 · Cited by 189
“Specifically, Shen and colleagues completed an uncontrolled case series of five critically ill patients with COVID-19 that had progressed to acute respiratory distress syndrome (ARDS) [58].”
BackgroundCicco, S., Cicco, G., Racanelli, V., & Vacca, A. (2020) · Mediators of Inflammation · doi:10.1155/2020/7527953 · Cited by 189
“Preliminary clinical experiences are promising [250], but are far from conclusive.”
BackgroundAntivirals for COVID-19: A critical review
Frediansyah, A., Tiwari, R., Sharun, K., Dhama, K., & Harapan, H. (2021) · Clinical Epidemiology and Global Health · doi:10.1016/j.cegh.2020.07.006 · Cited by 185
“Apart from antiviral drugs, several promising approaches are also being used to treat COVID-19 such as convalescent plasma, the use of which has shown a reduction in viral load and morbidity of patients.(154,155) IFN-⍺/β(156,157) and IL-6R inhibitor(158,159) have also showed promising effects and are currently being a…”
BackgroundI mmunosenescence and Inflammaging: Risk Factors of Severe COVID-19 in Older People
Pietrobon, A. J., Teixeira, F. M. E., & Sato, M. N. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.579220 · Cited by 183
Triggle, C. R., Bansal, D., Ding, H., Islam, M. M., Farag, E. A. B. A., Hadi, H. A., & Sultan, A. A. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.631139 · Cited by 177
“Despite encouraging anecdotal data from cohort studies of the beneficial role of CP in the management of COVID-19, this therapeutic approach is facing challenges including the availability of suitable donors to match the rising number of patients, inefficiency based on costeffectiveness as well as concerns of whether…”
BackgroundTreatment for emerging viruses: Convalescent plasma and COVID-19
Brown, B. L., & McCullough, J. (2020) · Transfusion and Apheresis Science · doi:10.1016/j.transci.2020.102790 · Cited by 161
“There have been several publications on convalescent plasma use for SARS-CoV-1 and MERS, including reviews/editorials, observational studies (retrospective, prospective, or case series), and a systematic literature review [14] [15] [16] [17] [18] .”
SARS-CoV-2 neutralizing antibody responses are more robust in patients with severe disease
Wang, P., Liu, L., Nair, M. S., Yin, M. T., Luo, Y., Wang, Q., Yuan, T., Mori, K., Solis, A. G., Yamashita, M., et al. (2020) · Emerging Microbes & Infections · doi:10.1080/22221751.2020.1823890 · Cited by 122
“only on a limited number of patients, and there were no careful measurements of neutralizing antibody titers to correlate with the clinical outcome [9].”
BackgroundSelf-citationButler, S. E., Crowley, A. R., Natarajan, H., Xu, S., Weiner, J. A., Lee, J., Wieland-Alter, W., Connor, R. I., Wright, P. F., & Ackerman, M. E. (2020) · doi:10.1101/2020.08.05.20168971 · Cited by 120
Current Status of COVID-19 Therapies and Drug Repositioning Applications
Altay, O., Mohammadi, E., Lam, S., Turkez, H., Boren, J., Nielsen, J., Uhlen, M., & Mardinoglu, A. (2020) · iScience · doi:10.1016/j.isci.2020.101303 · Cited by 98
“Although, two recent clinical trials have showed that remdesivir was not associated with dramatic clinical improvement, many clinical trials are underway (Beigel et al., 2020; Wang et al., 2020c).”
Neutralizing Antibody Responses in COVID-19 Convalescent Sera
Lee, W. T., Girardin, R. C., Dupuis, A. P., Kulas, K. E., Payne, A. F., Wong, S. J., Arinsburg, S., Nguyen, F. T., Mendu, D. R., Firpo-Betancourt, A., et al. (2021) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiaa673 · Cited by 93
“As a potential emergency therapy for 268 COVID-19, at least two groups have reported compassionate use and some success in 269 passive transfer of immune plasma into critically ill COVID-19 patients [23] [24].”
BackgroundAntibody Responses to SARS-CoV-2: Let’s Stick to Known Knowns
Baumgarth, N., Nikolich-Žugich, J., Lee, F. E.-H., & Bhattacharya, D. (2020) · The Journal of Immunology · doi:10.4049/jimmunol.2000839 · Cited by 84
Decay of Fc-dependent antibody functions after mild to moderate COVID-19
Lee, W. S., Selva, K. J., Davis, S. K., Wines, B. D., Reynaldi, A., Esterbauer, R., Kelly, H. G., Haycroft, E. R., Tan, H.-X., Juno, J. A., et al. (2020) · doi:10.1101/2020.12.13.20248143 · Cited by 80
Presence of antibody-dependent cellular cytotoxicity (ADCC) against SARS-CoV-2 in COVID-19 plasma
Tso, F. Y., Lidenge, S. J., Poppe, L. K., Peña, P. B., Privatt, S. R., Bennett, S. J., Ngowi, J. R., Mwaiselage, J., Belshan, M., Siedlik, J. A., et al. (2021) · PLOS ONE · doi:10.1371/journal.pone.0247640 · Cited by 68
Molecular mechanisms and epidemiology of COVID-19 from an allergist’s perspective
Hosoki, K., Chakraborty, A., & Sur, S. (2020) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2020.05.033 · Cited by 63
“In another study, transfusion of convalescent plasma containing neutralizing antibodies collected from the donors who had recovered from SARS-CoV-2 infection to 5 patients with COVID-19 and ARDS receiving mechanical ventilation improved their clinical status.(180) Likewise, the administration of convalescent plasma ha…”
Muslim, S., Nasrin, N., Alotaibi, F. O., Prasad, G., Singh, S. K., Alam, I., & Mustafa, G. (2020) · SN Comprehensive Clinical Medicine · doi:10.1007/s42399-020-00407-9 · Cited by 25
“One study in China evaluated the role of convalescent plasma in SARS-CoV-2 and demonstrated that 5 critically ill patients of COVID-19 with features of ARDS were given convalescent plasma and it was found that their body temp decreased, SOFA score decreased, Pao2/Fio2 improved, viral load decreased/became negative and…”
BackgroundSafety of Plasma Infusions in Parkinson's Disease
Parker, J. E., Martinez, A., Deutsch, G. K., Prabhakar, V., Lising, M., Kapphahn, K. I., Anidi, C. M., Neuville, R., Coburn, M., Shah, N., et al. (2020) · Movement Disorders · doi:10.1002/mds.28198 · Cited by 23
A review of COVID-19 convalescent plasma use in COVID-19 with focus on proof of efficacy
Devarasetti, P. K., Rajasekhar, L., Baisya, R., Sreejitha, K. S., & Vardhan, Y. K. (2021) · Immunologic Research · doi:10.1007/s12026-020-09169-x · Cited by 17
“dependent increase in titres of IgG and IgM in the recipients [5].”
Backgroundde Mattos Barbosa, M. G., Liu, H., Huynh, D., Shelley, G., Keller, E. T., Emmer, B. T., Sherman, E., Ginsburg, D., Kennedy, A. A., Tai, A. W., et al. (2021) · JCI Insight · doi:10.1172/jci.insight.147386 · Cited by 14
Piccoli, L., Park, Y.-J., Tortorici, M. A., Czudnochowski, N., Walls, A. C., Beltramello, M., Silacci-Fregni, C., Pinto, D., Rosen, L. E., Bowen, J. E., et al. (2020) · Cell · doi:10.1016/j.cell.2020.09.037 · Cited by 1,395
“…patients with convalescent plasma improved clinical outcomes and decreased viral loads (Duan et al., 2020; Li et al., 2020a; Liu et al., 2020b; Shen et al., 2020), highlighting the importance transfer of potently neutralizing human monoclonal Abs (mAbs) protected animals challenged with…”
Metadata
- Authors
- Shen, C., Wang, Z., Zhao, F., Yang, Y., Li, J., Yuan, J., Wang, F., Li, D., Yang, M., Xing, L., Wei, J., Xiao, H., Yang, Y., Qu, J., Qing, L., Chen, L., Xu, Z., Peng, L., Li, Y., Zheng, H., Chen, F., Huang, K., Jiang, Y., Liu, D., Zhang, Z., Liu, Y., & Liu, L.
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 2020-04-28
- Volume
- 323
- Issue
- 16
- Pages
- 1582
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- OpenAlex
- W3013742505
- Cited by
- 2,277
- References
- 23
- FWCI
- 66.30
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.